Skip to contentP
Petros Pharmaceuticals, Inc.
P
PTPIPetros Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue$1.67M$1.67Mno prior Q3 2022 on file Net Income-$4.55M-$4.55MN/M vs Q3 2022 EPS Diluted-$2.85-$2.85N/M vs Q3 2022 Gross Profit$1,266,182N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,046,202N/M Margins · derivedGross margin75.6%
Operating margin-287.0%
Net margin-271.7%
ended Sep 30, 2023 · filed Nov 15, 2023 · 46 d after period end